Description
What’s Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication)
There are several types of monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells (WBCs) that seek out and destroy harmful foreign substances – on the market and in development. What’s Trending in Monoclonal Antibodies looks at the market for these, which are finding wide application in many areas of medicine and biologic science, by structure, by target, and by indication, including the following information: monoclonal antibody revenues by structure, 2017 and forecast 2022 (chimeric, humanized, human, Others); leading chimeric, humanized and human mAb products market, 2017-2022; monoclonal antibody revenues by target, 2017 and forecast 2022 (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others); and monoclonal antibody revenues by indication, 2017 and Forecast 2022 (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other).
The report also goes beyond broad indication category to provide detail on the rheumatoid arthritis, Crohn’s disease/ulcerative colitis, psoriasis, other autoimmune, cancer (breast cancer, colon cancer, lymphoma, leukemia, myeloma, melanoma), multiple sclerosis, asthma, and macular degeneration mAb market segments, 2017-2022.
What’s Trending in Monoclonal Antibodies also looks at the market in terms of regional markets (United States, Europe, rest of world, global market) and the competitive situation, including company profiles of market leaders such as AbbVie, Johnson & Johnson, and Roche.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARYOVERVIEW
- Figure 1-1: Monoclonal Antibody Market Development, 1986-2022
SCOPE AND METHODOLOGYMARKET SUMMARY
- Figure 1-2: Monoclonal Antibody Market, 2017-2022 ($ millions)
CHAPTER TWO: INTRODUCTIONTHE DEVELOPMENT OF MONOCLONAL ANTIBODIES
- Figure 2-1: Monoclonal Antibody Approvals by Year, FDA and EMA, 1990 through December 2017
NAMING MONOCLONAL ANTIBODIES
- Table 2-1: Monoclonal Antibody Source Identifiers
- Table 2-2: Monoclonal Antibody Disease or Target Class Identifiers
- Table 2-3: Examples of Monoclonal Antibodies by Name Origin
New Monoclonal Antibody Nomenclature Rules
- Table 2-4: USAN Requirements for Monoclonal Antibodies
DEVELOPMENT OUTLOOK
- Table 2-5: Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others, Total)
- Figure 2-2: Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others)
- Figure 2-3: Monoclonal Antibody Development Pipeline, Distribution of Projects by Therapeutic Class, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others)
- Figure 2-4: Monoclonal Antibody Development Pipeline, Distribution of Projects by Phase, 2017 (Registration, Phase I, Phase II, Phase III)
CHAPTER THREE: MONOCLONAL ANTIBODY MARKETS BY STRUCTURE
- Figure 3-1: Monoclonal Antibodies by Structure – Mouse, Chimeric, Humanized, Human
MARKET OVERVIEW
- Table 3-1: Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions) (Chimeric, Humanized, Human, Others, Total)
- Figure 3-2: Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions) (Chimeric, Humanized, Human, Others)
- Figure 3-3: Monoclonal Antibody Market Distribution by Structure, 2017 (%) (Chimeric, Humanized, Human, Others)
- Figure 3-4: Monoclonal Antibody Market Distribution by Structure, 2022 (%) (Chimeric, Humanized, Human, Others)
Chimeric
- Table 3- 2: Leading Products: Chimeric Structure mAb Market, 2017-2022 ($ millions)
- Humanized
- Table 3-3: Leading Products: Humanized Structure mAb Market, 2017-2022 ($ millions)
Human
- Table 3-4: Leading Products: Human Structure mAb Market, 2017-2022 ($ millions)
CHAPTER FOUR: MONOCLONAL ANTIBODY MARKETS BY TARGETMARKET OVERVIEW
- Figure 4-1: Monoclonal Antibodies by Target – TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6 Examples
- Table 4-1: Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions) (TNF, VEGF, HER2, PD-1, CD20, IL12/IL23, TNFSF11, IL17, EGFR, IL6, PD-L1, Others, Total)
- Figure 4-2: Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions) (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others)
- Figure 4-3: Monoclonal Antibody Market Distribution by Target, 2017 (%) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)
- Figure 4-4: Monoclonal Antibody Market Distribution by Target, 2022 (%) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)
CHAPTER FIVE: MONOCLONAL ANTIBODY MARKETS BY INDICATIONMARKET OVERVIEW
- Table 5-1: Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other, Total)
- Figure 5-1: Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)
- Figure 5-2: Monoclonal Antibody Market Distribution by Indication, 2017 (%) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)
- Figure 5-3: Monoclonal Antibody Market Distribution by Indication, 2022 (%) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)
Autoimmune Diseases
- Table 5-2: Rheumatoid Arthritis mAb Market, 2017-2022 ($ millions)
- Table 5-3: Crohn’s Disease/Ulcerative Colitis mAb Market, 2017-2022 ($ millions)
- Table 5-4: Psoriasis mAb Market, 2017-2022 ($ millions)
- Table 5-5: Other Autoimmune Disease mAb Market, 2017-2022 ($ millions)
Oncology Indications
- Table 5-6: Cancer Treatment mAb Market by Type, 2017-2022 ($ millions) (Breast Cancer, Colon Cancer, Lymphoma, Leukemia, Myeloma, Melanoma)
- Table 5-7: Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)
- Figure 5-4: Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)
Neurological Indications
- Table 5-8: Multiple Sclerosis mAb Market, 2017-2022 ($ millions)
Respiratory Treatments
- Table 5-9: Asthma mAb Market, 2017-2022 ($ millions)
OTHER AREAS OF TREATMENT
- Table 5-10: Macular Degeneration mAb Market, 2017-2022 ($ millions)
CHAPTER SIX: MARKET SUMMARYMARKET INFLUENCESGlobal Demographics
- Table 6-1: Global Population, through 2050 (population in millions)
- Figure 6-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
Chronic Diseases
- Figure 6-2: Mortality: Chronic vs. Acute, 2015
Cost Containment
- Table 6-2: The Cost of Monoclonal Antibodies (Soliris, Ilaris, Erbitux, Opdivo, Avastin, Yervoy, Stelara, Xolair, Perjeta, Tysabri, Cosentyx, Simponi, Vectibix, Herceptin, Humira, Entyvio, Rituxan, Synagis, Remicade)
REIMBURSEMENT LANDSCAPE: A DECIDING FACTOR FOR SUCCESSTHE BIOSIMILAR MOVEMENTREGIONAL MARKET OVERVIEW
- Table 6-3: Monoclonal Antibody Market Summary by Geographical Region, 2017-2022 ($ millions) (United States, Europe, Rest of World, Global Market)
- Figure: 6-3: Monoclonal Antibody Market Summary by Geographic Region, 2017 ($ millions) (United States, Europe, Rest of World)
LEADING PRODUCTS
- Table 6-4: Leading Monoclonal Antibodies based on 2017 Sales ($ millions)
MARKET BREAKDOWN OF MONOCLONAL ANTIBODIES
- Figure 6-4: Monoclonal Antibody Market by Structure, 2017 and 2022 ($ millions) (Chimeric, Humanized, Human, Others)
- Figure 6-5: Monoclonal Antibody Market by Target, 2017 and 2022 ($ millions) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)
- Figure 6-6: Monoclonal Antibody Market by Indication, 2017 and 2022 ($ millions) (Rheumatoid Arthritis, Breast Cancer, Melanoma, Crohn’s Disease/Ulcerative Colitis, Colon Cancer, Lymphoma, Psoriasis, Macular Degeneration, Asthma, Multiple Sclerosis, Osteoporosis, Myeloma, RSV, Leukemia, Other Indications)
COMPETITOR SUMMARY
- Genentech/Roche
- AbbVie
- Janssen Biotech/J&J
- Bristol-Myers Squibb
- Merck & Co
- Novartis
- Amgen
- Alexion
- Biogen
- Eli Lilly & Co.
- Table 6-5: Monoclonal Antibody Competitor Market Share, 2017 ($ millions)
CHAPTER SEVEN: COMPANY PROFILESABBVIE
- Table 7-1: AbbVie Corporate Summary
ABLYNX
- Table 7-2: Ablynx Corporate Summary
AGENSYS
- Table 7-3: Agensys (with Astellas) Corporate Summary
ALDER BIOPHARMACEUTICALS
- Table 7-4: Alder Biopharmaceuticals Corporate Summary
ALEXION PHARMACEUTICALS
- Table 7-5: Alexion Pharmaceuticals Corporate Summary
ALLERGAN
- Table 7-6: Allergan Corporate Summary
AMGEN
- Table 7-7: Amgen Corporate Summary
APTEVO THERAPEUTICS
- Table 7-8: Aptevo Corporate Summary
ASTRAZENECA/MEDIMMUNE
- Table 7-9: AstraZeneca/MedImmune Corporate Summary
BAYER
- Table 7-10: Bayer Corporate Summary
BIOCON LTD
- Table 7-11: Biocon Corporate Summary
BIOGEN INC.
- Table 7-12: Biogen Corporate Summary
BIOINVENT INTERNATIONAL
- Table 7-13: BioInvent Corporate Summary
BIOTEST AG
- Table 7-14: Biotest AG Corporate Summary
BOEHRINGER INGELHEIM GMBH
- Table 7-15: Boehringer Ingelheim Corporate Summary
CBT PHARMACEUTICALS
- Table 7-16: CBT Corporate Summary
CELGENE
- Table 7-17: Celgene Corporate Summary
CELLDEX THERAPEUTICS
- Table 7-18: Celldex Therapeutics Corporate Summary
CELLTRION, INC.
- Table 7-19: Celltrion Corporate Summary
COHERUS BIOSCIENCES, INC
- Table 7-20: Coherus Biosciences Corporate Summary
CYTODYN
- Table 7-21: CytoDyn Corporate Summary
EISAI
- Table 7-22: Eisai Corporate Summary
ELEVEN BIOTHERAPEUTICS
- Table 7-23: Eleven Biotherapeutics Corporate Summary
ELI LILLY & CO.
- Table 7-24: Eli Lilly & Co. Corporate Summary
FIBROGEN INC.
- Table 7-25: FibroGen Inc. Corporate Summary
FIVE PRIME THERAPEUTICS
- Table 7-26: Five Prime Therapeutics Corporate Summary
FUJIFILM KYOWA KIRIN BIOLOGICS
- Table 7-27: Fujifilm Kyowa Kirin Biologics Corporate Summary
GENMAB A/S
- Table 7-28: Genmab A/S Corporate Summary
GILEAD SCIENCES
- Table 7-29: Gilead Sciences Corporate Summary
GLAXOSMITHKLINE PLC
- Table 7-30: GlaxoSmithKline Corporate Summary
HUMANIGEN, INC. (PREVIOUSLY KALOBIOS PHARMACEUTICALS)
- Table 7-31: Humanigen Inc. Corporate Summary
IMMUNE PHARMACEUTICALS
- Table 7-32: Immune Pharmaceuticals Corporate Summary
IMMUNOGEN INC.
- Table 7-33: ImmunoGen Inc. Corporate Summary
IMMUNOMEDICS INC.
- Table 7-34: Immunomedics Inc. Corporate Summary
INNATE PHARMA
- Table 7-35: Innate Pharma Corporate Summary
INTERVEXION THERAPEUTICS
- Table 7-36: InterveXion Therapeutics Corporate Summary
JOHNSON & JOHNSON
- Table 7-37: Johnson & Johnson Corporate Summary
KYOWA HAKKO KIRIN CO, LTD
- Table 7-38: Kyowa Hakko Kirin Corporate Summary
MACROGENICS
- Table 7-39: MacroGenics Corporate Summary
MAPP BIOPHARMACEUTICAL
- Table 7-40: Mapp Corporate Summary
MERCK & COMPANY
- Table 7-41: Merck Corporate Summary
MERRIMACK PHARMACEUTICALS
- Table 7-42: Merrimack Corporate Summary
MOMENTA PHARMACEUTICALS INC
- Table 7-43: Momenta Pharmaceuticals Corporate Summary
MORPHOSYS
- Table 7-44: MorphoSys Corporate Summary
MORPHOTEK
- Table 7-45: Morphotek Corporate Summary
MYLAN N.V.
- Table 7-46: Mylan Corporate Summary
NASCENT BIOTECH
- Table 7-47: Nascent Biotech Corporate Summary
NEURIMMUNE
- Table 7-48: Neurimmune Corporate Summary
NORDIC NANOVECTOR
- Table 7-49: Nordic Nanovector Corporate Summary
NOVARTIS/SANDOZ
- Table 7-50: Novartis/Sandoz Corporate Summary
NOVIMMUNE SA
- Table 7-51: Novimmune SA Corporate Summary
ONCOMED PHARMACEUTICALS
- Table 7-52: OncoMed Pharmaceuticals Corporate Summary
ONCOQUEST
- Table 7-53: OncoQuest Corporate Summary
ONCTERNAL THERAPEUTICS
- Table 7-54: Oncternal Therapeutics Corporate Summary
PFIZER, INC.
- Table 7-55: Pfizer Corporate Summary
REGENERON PHARMACEUTICALS
- Table 7-56: Regeneron Corporate Summary
ROCHE
- Table 7-57: Roche Corporate Summary
SAMSUNG BIOEPIS CO LTD
- Table 7-58: Samsung Bioepis Corporate Summary
SANOFI
- Table 7-59: Sanofi Corporate Summary
SEATTLE GENETICS
- Table 7-60: Seattle Genetics Corporate Summary
SHIRE PLC
- Table 7-61: Shire PLC Corporate Summary
SORRENTO THERAPEUTICS
- Table 7-62: Sorrento Therapeutics Corporate Summary
TAIMED BIOLOGICS
- Table 7-63: TaiMed Biologics Corporate Summary
TAKEDA ONCOLOGY
- Table 7-64: Takeda Oncology Corporate Summary
TESARO
- Table 7-65: TESARO Corporate Summary
TEVA PHARMACEUTICAL INDUSTRIES LTD
- Table 7-66: Teva Corporate Summary Corporate Summary
TG THERAPEUTICS
- Table 7-67: TG Therapeutics Corporate Summary
THROMBOGENICS
- Table 7-68: ThromboGenics Corporate Summary
UCB S.A.
- Table 7-69: UCB S.A. Corporate Summary
UNUM THERAPEUTICS
- Table 7-70: Unum Therapeutics Corporate Summary
VITAERIS
- Table 7-71: Vitaeris Corporate Summary
XBIOTECH
- Table 7-72: XBiotech Corporate Summary
XENCOR
- Table 7-73: Xencor Corporate Summary
XOMA
- Table 7-74: XOMA Corporate Summary
Y-MABS THERAPEUTICS
- Table 7-75: Y-mAbs Therapeutics Corporate Summary